Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-B6A + SSGJ-707 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-B6A | SGN B6A|SGNB6A|anti-integrin beta-6/MMAE ADC SGN-B6A|Sigvotatug vedotin | SGN-B6A is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting integrin beta-6 linked to monomethyl auristatin E, which delivers the anti-microtubule agent to integrin beta-6-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37619980). | ||
| SSGJ-707 | PF-08634404|SSGJ 707|SSGJ707|PF08634404|PF 08634404 | PD-L1/PD-1 antibody 136 VEGF Antibody 17 | SSGJ-707 (PF-08634404) is a bispecific antibody that targets PDCD1 (PD-1) and VEGF, which potentially decreases tumor growth (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_3). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07227298 | Phase Ib/II | SSGJ-707 SGN-B6A + SSGJ-707 | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Recruiting | USA | 2 |